Moreover, the ability of HEXIM1 to inhibit major tumor promoting pathways likely contributes to the effective targeting of multiple breast cancer subtypes with HEXIM1 inducers, alone or in combination with other therapeutics. This evidence concerns the gene HEXIM1 and breast carcinoma.